A multicenter randomized phase III trial of nonpegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide (MC) versus liposome-encapsulated doxorubicin citrate plus vinorelbine (MV) as first-line treatment in locally advanced (LABC) or metastatic breast cancer (MBC).Vito Lorusso, Giuseppe Colucci, Roberto Bordonaro et al.|Journal of Clinical Oncology|2011Cited by 0